* Borderline or locally advanced pancreatic adenocarcinoma
* Metastatic pancreatic adenocarcinoma without symptomatic peritoneal carcinomatosis
* metastatic colon/rectal cancer without symptomatic peritoneal carcinomatosis
Patients with an indication for chemotherapy (induction treatment or treatment of metastatic disease)
Patients able to eat orally at the time of inclusion in the study
Patients with a performance status (PS) score ≤2
Patients who agree to provide stool and saliva samples
Patients who have given their written informed consent
Patients affiliated with the French social security system
You may not be if
Pregnant or breastfeeding women
Patients who have received antibiotics within 3 weeks prior to the first chemotherapy treatment (excluding antibiotic prophylaxis administered in the context of surgery or endoscopy).
Individuals receiving psychiatric care that may interfere with their ability to respond to questionnaires (in the investigator's opinion)
Persons deprived of their liberty or subject to legal protection measures (guardianship, curatorship)
Patients participating in another interventional study with medication
Patients who have undergone chemotherapy for another malignant tumor in the last 12 months.
Patients with another synchronous malignant tumor, with the exception of adequately treated carcinoma in situ of the cervix or squamous cell carcinoma of the skin, or limited basal cell or squamous cell skin cancer. This cancer must then be adequately controlled.
Patients with symptomatic brain and/or meningeal metastases.
Patients who have undergone digestive resection (excluding appendectomy or cholecystectomy \>12 months ago).
Patients with symptomatic peritoneal carcinomatosis prior to the start of chemotherapy.
Clareo Health | Association Between Composition of the Gut Microbiota and Nutritional Status in Digestive Oncology
